Vascarta Announces Positive Clinical Trial Results for Topical/Transdermal Curcumin Gel VAS-101 in Knee Osteoarthritis

Follow Drugslib on

SUMMIT, N.J., April 1, 2026 /PRNewswire/ -- Vascarta Inc. today announced the publication of results from a randomized, double-blind, placebo-controlled clinical trial evaluating VAS-101, the company's investigational topical/transdermal curcumin gel, for the treatment of knee pain associated with osteoarthritis. The study appears in the peer-reviewed journal Frontiers in Pain Research. Frontiers | The effect of a topical curcumin formulation (VAS-101) on knee pain in adults with knee osteoarthritis: a randomised, double-blind, placebo-controlled study

Amazon Big Spring Sale - Up to 40% off
  • Novel Transdermal Curcumin Formulation Demonstrates Pain Reduction and Improved Quality of Life in Phase 1b Clinical Trial
  • Study published in Frontiers in Pain Research reports significant reduction in knee pain with topical curcumin formulation

    • The clinical trial demonstrated that participants using VAS-101 experienced statistically significant reductions in knee pain compared with placebo, along with a favorable safety and tolerability profile.

    Dr. Adrian Lopresti, Managing Director of Clinical Trials Australia and principal investigator, stated, "The results of this study demonstrate that, in people with knee osteoarthritis, the topical application of VAS-101 reduced knee pain within 28 days, with clinically meaningful improvements occurring in approximately 40% of participants. VAS-101 may represent a promising option for individuals experiencing knee osteoarthritis."

    Study DesignThe randomized, double-blind, placebo-controlled trial enrolled 60 adults aged 45–75 with knee osteoarthritis. Participants applied either 0.1 mL VAS-101 or 0.1 mL placebo gel to the affected knee every other day for 28 days.

    Researchers assessed outcomes using several validated measures, including:

  • KOOS pain subscale (primary endpoint)
  • Daily pain ratings
  • Performance-based physical function tests
  • Use of rescue oral pain medication

    • Key FindingsResults from the study showed that VAS-101 produced meaningful improvements in pain outcomes compared with placebo:

  • Significant improvement in KOOS pain score (β: 5.12; 95% CI: 0.47–9.77; p = 0.041)
  • Significant reduction in daily pain ratings (p = 0.005)
  • 39.3% of participants using VAS-101 reported feeling "much improved" or "very much improved," compared with 13.3% in the placebo group (p = 0.019)
  • 32.1% of participants achieved a Minimal Clinically Important Difference in symptoms, compared with 13.3% with placebo

    • VAS-101 was well tolerated, with no significant adverse reactions reported. Temporary skin staining, a known characteristic of topical curcumin, was observed but resolved within two to three days after discontinuation.

    ImplicationsThe study suggests that topical delivery of curcumin may offer a promising non-oral therapeutic approach to managing osteoarthritis-related knee pain, potentially addressing limitations associated with oral formulations.

    While further research with larger patient populations and longer treatment durations is needed, these findings highlight the potential role of VAS-101 in managing osteoarthritis pain," said Joel Friedman, M.D., Ph.D., inventor of Vascarta's patented transdermal drug delivery technology, Professor Emeritus at Albert Einstein College of Medicine, and Chief Scientific Officer.

    Chairman and CEO Richard Prince, Ph.D. added: "These data indicate the potential of VAS-101 to become the standard of care in osteoarthritis. We intend to accelerate our efforts in the development of VAS-101 for osteoarthritis with the anticipated filing of an Investigational New Drug Application to the United States Food & Drug Administration later this year."

    About Knee OsteoarthritisKnee osteoarthritis is a degenerative joint condition affecting millions of adults worldwide. It is characterized by chronic pain, stiffness, reduced mobility, and progressive deterioration of joint cartilage.

    About VAS-101VAS-101 is an investigational topical curcumin formulation developed and patented by Vascarta. It is designed to deliver curcumin through the skin directly into affected joints, potentially providing localized and enhanced systemic anti-inflammatory and analgesic effects.

    About VascartaVascarta Inc. is a clinical-stage pharmaceutical company focused on developing therapies to address chronic pain and inflammation. The company's proprietary drug delivery platform supports a growing pipeline of therapies targeting inflammatory diseases and cancer.

    The company's lead candidate, Vasceptor® (VAS-101), is a topically applied transdermal formulation utilizing curcumin as its active pharmaceutical ingredient. By bypassing the gastrointestinal tract and first-pass liver metabolism, the transdermal route may enhance curcumin delivery into systemic circulation compared with oral formulations.

    SOURCE Vascarta Inc

    Source: HealthDay

    More news resources

  • FDA Medwatch Drug Alerts
  • Daily MedNews
  • News for Health Professionals
  • New Drug Approvals
  • New Drug Applications
  • Clinical Trial Results
  • Generic Drug Approvals
  • Drugs.com Podcast

    • Subscribe to our newsletter

    Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

    Posted : 2026-04-03 08:59

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords